Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02979353 · ClinicalTrials.gov registry record · NA
A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy
A NA study of Polypharmacy and Care Transitions, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 372
- Enrollment target
- 1
- Study location
NCT02979353: Completed NA study of Polypharmacy and Care Transitions, sponsored by Vanderbilt University Medical Center.
NCT02979353 is a NA study of Polypharmacy and Care Transitions that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 372 participants, below the 1,496-participant average among 11 other Polypharmacy trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02979353, a NA study of Polypharmacy and Care Transitions, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 372 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, controlled trial will evaluate the effects of an intervention to reduce exposure to medications among hospitalized older adults discharged to skilled nursing facilities (SNFs). The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences. The investigators will evaluate the effects of the intervention on the total number of medications prescribed to patients at hospital and SNF discharge and at home 90-days after SNF discharge along with the prevalence of eight geriatric syndromes, medication adherence, and health status.
Primary Outcome
The number of medications a participant is taking. This includes all prescribed and over-the-counter medications and both scheduled and as-needed (PRN) medications.
Conditions Studied
Interventions
- BEHAVIORAL Shed-Meds: A Patient-Centered Deprescribing Intervention
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2021-05-01 |
| Phase | NA |
What the finished NCT02979353 record still lists
NCT02979353 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, below the 1,496-participant average among 11 other Polypharmacy trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Polypharmacy appearing as the primary indexed condition, and to 1 intervention - of which Shed-Meds: A Patient-Centered Deprescribing Intervention is the first listed.
NCT02979353 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02979353 about?
NCT02979353 is a clinical study titled "A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy". This randomized, controlled trial will evaluate the effects of an intervention to reduce exposure to medications among hospitalized older adults discharged to skilled nursing facilities (SNFs). The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopp...
What is the current status of trial NCT02979353?
This trial is currently completed. It is a NA study. The enrollment target is 372 participants. The study started on 2017-03-06. Estimated completion is 2021-05-01.
What conditions does trial NCT02979353 study?
This clinical trial studies the following conditions: Polypharmacy, Care Transitions, Geriatric Syndromes.
What interventions are being tested in trial NCT02979353?
The interventions under investigation include: Shed-Meds: A Patient-Centered Deprescribing Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT02979353?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02979353 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polypharmacy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02979353's enrollment target sits among peer trials
372 8th of 11 higher than 4 of 11 other Polypharmacy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polypharmacy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Medication Management in World Trade Center Responders
RECRUITING · NA
-
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
RECRUITING · NA
-
Effectiveness of PGx Testing
ACTIVE NOT RECRUITING · NA
-
Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial
ACTIVE NOT RECRUITING · NA
-
Preemptive Pharmacogenomics Testing Among Geriatric Patients
ACTIVE NOT RECRUITING · NA
-
Pharmacist Intervention to Reduce Post-Hospitalization Utilization
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI